Drug
SB206 12%
SB206 12% is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Phase Distribution
Ph phase_2
1
33%
Ph phase_3
2
67%
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
2(66.7%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(3)
Detailed Status
Completed3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (33.3%)
Phase 32 (66.7%)
Trials by Status
completed3100%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_2
A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum
NCT03436615
completedphase_3
A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC
NCT03927703
completedphase_3
A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)
NCT03927716
Clinical Trials (3)
Showing 3 of 3 trials
NCT03436615Phase 2
A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum
NCT03927703Phase 3
A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC
NCT03927716Phase 3
A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3